VIVO
Meridian Bioscience Inc.
$4.52
-$0.15(-3.21%)
32
Overall
--
Value
36
Tech
28
Quality
Market Cap
$126.98M
Volume
2.18M
52W Range
$1.20 - $8.88
Target Price
$NaN
Order:
Income Statement
| Metric | Trend | Chart | 2018 Mar | 2019 Mar | 2019 Jun | 2020 Jun | 2021 Jun | 2022 Jun | 2023 Jun | 2024 Jun | 2025 Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | |||||||||||
| Total Revenue | $33.6M | $39.0M | $43.5M | $48.0M | $24.0M | $20.6M | $4.1M | $16.0K | $61.0K | ||
| Total Revenue | $33.6M | $39.0M | $43.5M | $48.0M | $24.0M | $20.6M | $4.1M | $16.0K | $61.0K | ||
| COST OF GOODS SOLD | |||||||||||
| Cost of Revenue | $-28.5M | $-32.7M | $-37.5M | $-27.7M | $-19.6M | $-20.3M | $8.1M | $27.0K | $50.0K | ||
| GROSS PROFIT | |||||||||||
| Gross Profit | $5.1M | $6.3M | $6.1M | $5.4M | $4.4M | $259.0K | $-4.1M | $-11.0K | $11.0K | ||
| OPERATING EXPENSES | |||||||||||
| Operating Expenses | $14.1M | $12.3M | $12.0M | $10.4M | $11.1M | $23.6M | $7.7M | $8.7M | $8.8M | ||
| Research & Development | -- | -- | $3.3M | -- | -- | -- | -- | -- | -- | ||
| Selling, General & Administrative | $12.8M | $7.7M | $7.2M | $8.7M | $9.7M | $13.3M | $6.4M | $7.5M | $8.2M | ||
| Selling & Marketing Expenses | -- | -- | -- | $3.2M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $12.8M | $7.7M | $7.2M | $5.5M | $9.7M | $13.3M | $6.4M | $7.5M | $8.2M | ||
| Salaries & Wages | $-17.0M | $-17.4M | $-4.1M | $-16.5M | $-17.4M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $1.3M | $1.4M | $1.4M | $1.8M | $1.5M | $1.6M | $1.3M | $1.1M | $517.0K | ||
| Depreciation & Amortization | $1.3M | $1.4M | $1.4M | $1.8M | $1.5M | $10.2M | $1.3M | $1.1M | $517.0K | ||
| Amortization | $840.0K | $990.0K | $-223.0K | $868.0K | $815.0K | $850.0K | $831.0K | $384.0K | $360.0K | ||
| Other Operating Expenses | -- | -- | -- | $3.2M | $-2.8M | $-100.0K | $-113.0K | $-89.0K | -- | ||
| OPERATING INCOME | |||||||||||
| Operating income | $-9.0M | $-6.0M | $-5.9M | $-3.3M | $-6.7M | $-23.3M | $-11.7M | $-8.7M | $-8.7M | ||
| EBITDA | $-36.3M | $-12.5M | $-12.8M | $-5.8M | $-11.1M | $-21.0M | $-11.1M | $-36.7M | $-7.6M | ||
| NON-OPERATING ITEMS | |||||||||||
| Interest Expense (Non-Operating) | $-3.4M | $-3.2M | $-3.3M | $-3.2M | -- | -- | $6.8M | $6.0M | $7.0M | ||
| Interest Income Operating | -- | $-3.0M | -- | -- | $1.6M | -- | -- | -- | -- | ||
| Intinc | $9.0K | $4.0K | $-796.0K | $33.0K | $2.2M | $173.0K | $1.2M | $1.4M | $3.6M | ||
| Net Non-Operating Interest Income/Expense | $9.0K | $4.0K | $2.5M | $33.0K | $2.2M | $173.0K | $-5.7M | $-4.6M | $-3.5M | ||
| Gain on Sale of Securities | -- | -- | -- | -- | -- | -- | -- | $89.0K | $16.0K | ||
| Other Income/Expense | $9.5M | $5.6M | $-2.7M | $3.8M | $-1.7M | $19.9M | $-3.6M | $-89.0K | $-16.0K | ||
| Other Special Charges | $2.0M | $11.9M | $11.2M | $724.0K | $960.0K | $662.0K | -- | -- | -- | ||
| SPECIAL ITEMS | |||||||||||
| Restructring And Mn A Income | $5.3M | $2.0M | $2.4M | $3.4M | $2.9M | $443.0K | $1.7M | $1.4M | $412.0K | ||
| Special Income Charges | $-15.5M | $-2.0M | $-2.4M | $-3.4M | $-3.7M | $-443.0K | $-2.1M | $-31.1M | $-2.9M | ||
| Impairment of Capital Assets | $10.2M | -- | -- | -- | $2.5M | -- | $421.0K | $29.7M | $2.5M | ||
| PRE-TAX INCOME | |||||||||||
| EBIT | $-37.5M | $-13.9M | $-14.3M | $-7.6M | $-13.4M | $-22.9M | $-12.7M | $-38.3M | $-8.1M | ||
| Pre-Tax Income | $-34.1M | $-10.7M | $-11.0M | $-4.1M | $-8.2M | $-22.9M | $-19.5M | $-44.3M | $-15.1M | ||
| INCOME TAX | |||||||||||
| Tax Provision | $-6.3M | $557.0K | $353.0K | $713.0K | $-138.0K | $-2.0M | $559.0K | $-1.6M | $-691.0K | ||
| NET INCOME | |||||||||||
| Net Income | $-27.7M | $-14.2M | $-6.0M | $-11.2M | $-14.3M | $-42.1M | $-24.4M | $-43.5M | $-12.8M | ||
| Net Income (Continuing Operations) | $-27.7M | $-14.2M | $-6.0M | $-11.2M | $-14.3M | $-42.1M | $-20.1M | $-42.7M | $-14.4M | ||
| Net Income (Discontinued Operations) | $-27.7M | $-14.2M | $-6.0M | $-11.2M | $-14.3M | $-42.1M | $-24.4M | $-43.5M | $-12.8M | ||
| Net Income (Common Stockholders) | $-27.7M | $-14.2M | $-6.0M | $-11.2M | $-14.3M | $-42.1M | $-24.4M | $-43.5M | $-12.8M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-12.3M | $-14.8M | $-12.9M | ||
| TOTALS | |||||||||||
| Total Expenses | $-14.4M | $-20.4M | $-25.5M | $-17.3M | $-8.5M | $3.2M | $15.8M | $8.7M | $8.8M | ||
| SHARE & EPS DATA | |||||||||||
| Average Shares Outstanding | $13.6M | $13.6M | $13.6M | $13.6M | $16.3M | $20.7M | $2.5M | $3.1M | $6.7M | ||
| Average Shares Outstanding (Diluted) | $13.4M | $17.1M | $54.4M | $29.6M | $29.2M | $40.5M | $2.5M | $3.1M | $6.7M | ||
| Shares Outstanding | $13.6M | $13.6M | $13.6M | $13.6M | $18.5M | $21.3M | $27.5M | $27.5M | $12.5M | ||
| Basic EPS | $-2.06 | $-0.83 | $-0.11 | $-0.38 | $-0.49 | $-1.04 | $-9.87 | $-15.17 | $-1.92 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $-0.49 | $-1.01 | $-9.87 | $-15.17 | $-1.92 | ||
| Diluted EPS | $-2.06 | $-0.83 | $-0.11 | $-0.38 | $-0.49 | $-1.04 | $-9.87 | $-15.17 | $-1.92 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $-0.49 | $-1.01 | $-9.87 | $-15.17 | $-1.92 | ||
| OTHER METRICS | |||||||||||
| Acquired In Process Rn D | -- | -- | -- | -- | $1.6M | -- | -- | -- | -- | ||
| Acquired In Process Rn D Income | $222.0K | -- | -- | -- | -- | $-21.6M | -- | -- | -- | ||
| Acquisition Expense | -- | $3.2M | -- | -- | -- | -- | $55.0K | -- | -- | ||
| Basic Discontinuous Operations | -- | -- | -- | -- | -- | $-0.03 | $-0.17 | -- | -- | ||
| Depletion | -- | -- | -- | -- | -- | $8.6M | -- | -- | -- | ||
| Development Expense | -- | -- | $3.3M | -- | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | -- | -- | $-0.03 | $-0.17 | -- | -- | ||
| Earnings from equity interest | $-11.1M | -- | -- | $-1.0M | -- | -- | $-254.0K | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | $-11.1M | -- | -- | $-1.0M | -- | -- | $-254.0K | -- | -- | ||
| Gain On Sale Of P P E | $1.4M | $-5.6M | $2.7M | $1.6M | $769.0K | $1.0M | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | -- | $69.0K | $-625.0K | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | $-5.3M | -- | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | $-387.0K | -- | -- | -- | -- | ||
| Net Income Discontinuous Operations | $1.4M | $-2.6M | $38.0K | $1.6M | $69.0K | $-625.0K | $-4.3M | $-881.0K | $1.6M | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | $8.1M | $27.0K | $50.0K | ||
| Other Gand A | $12.8M | $7.7M | $7.2M | $5.5M | $9.7M | $13.3M | $6.4M | $7.5M | $8.2M | ||
| Provision For Gain Loss On Disposal | $1.4M | $-2.6M | $38.0K | $1.6M | -- | -- | -- | -- | -- | ||
| Realized Capital Gain | -- | -- | -- | $-5.1M | -- | -- | -- | -- | -- | ||
| Selling Expense | -- | -- | -- | $3.2M | -- | -- | -- | -- | -- | ||
| Restruct | $5.3M | $2.0M | $2.4M | $3.4M | $2.9M | $443.0K | $1.7M | $1.4M | $412.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VIVO | $4.52 | -3.2% | 2.18M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Meridian Bioscience Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW